Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

Not Recruiting

Trial ID: NCT00285857


The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.

Official Title

A Phase 2 Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer

Stanford Investigator(s)

Allison W. Kurian, M.D., M.Sc.
Allison W. Kurian, M.D., M.Sc.

Professor of Medicine (Oncology) and of Epidemiology and Population Health



* Female
* Increased inherited risk of breast cancer, as defined by:

* Known deleterious mutation in BRCA1, BRCA2, or other high-risk mutation
* Family history conveying at least a 2-fold increase in breast cancer risk
* ECOG performance status 0
* Normal organ and marrow function, including complete blood count and comprehensive metabolic panel within normal institutional limits
* Subject agreement to limit alcoholic beverage consumption to three alcoholic drinks per week.


* Prior history of invasive breast cancer less than 2 years previously (EXCEPTION: stage III or lower breast cancer \> 2 years ago)
* Current or history of other cancers (EXCEPTION: non-melanoma skin cancer, or stage III or cancer without evidence of recurrence for 5 years
* Initial mammogram, breast MRI, or clinical breast examination prompts recommendation for biopsy by study investigators.
* Evidence of malignant cytology on initial rpFNA.
* Use of other investigational agents.
* Use of tamoxifen or selective estrogen response modifiers (SERMS), including raloxifene, within the last 2 years.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to lovastatin.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements.
* Currently receiving lovastatin and cyclosporine, gemfibrozil, erythromycin, fibrates or niacin, (unless discontinued for study participation)
* No evidence of active liver disease, nor elevation of serum transaminases (prior history of liver disease, if not currently active, is not an exclusion)
* No evidence of myopathy or myositis, including symptoms of generalized muscle aches or weakness, muscle tenderness, or elevation in creatine phosphokinase.
* Lactating (breastfeeding)


drug: Lovastatin

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Meredith Mills

New Trial Alerts